logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Aducanumab for mild cognitive impairment due to Alzheimer’s disease

< Back

Aducanumab for mild cognitive impairment due to Alzheimer’s disease

Drugs

Neurology and Neurosurgery

March 2020


Aducanumab is currently in clinical development for the treatment of mild cognitive impairment due to Alzheimer’s disease. Alzheimer’s disease is a progressive neurological disease which is caused by loss of function and death of neurones in the brain. It is the most common type of dementia. One of the early symptoms of Alzheimer’s disease is mild cognitive impairment where a person may have difficulty with memory, reasoning, attention or visual depth perception. The difficulties are significant enough to be noticed by the patient and their family or friends but not enough to affect their ability to carry out everyday activities. Current treatment optionsfor Alzheimer’s disease are aimed at relieving the symptoms (including cognitive impairment) rather than stopping the progression of the disease.

Aducanumab is a highly selective human antibody that specifically targets the β-amyloid (Aβ) protein which builds up in abnormal levels in the brain of people with Alzheimer’s disease. High levels of Aβ result in the protein clumping together to form plaques which disrupt neurone function. Aducanumab is given through intravenous infusion and if licensed, would offer an additional treatment option for Alzheimer’s disease and the first to treat the underlying disease rather than the symptoms.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts